UniPharma Co., Ltd. (6621.TWO)
TWD 13.85
(-0.72%)
TWD 13.85
(-0.72%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 12.03 Million | -31.65 Million | -12.93 Million | -17.17 Million | -9.24 Million |
| Net Income | -21.81 Million | -7.02 Million | -74.4 Million | -55.35 Million | -25.04 Million |
| Depreciation & Amortization | 5.54 Million | 5.53 Million | 10.78 Million | 11.17 Million | 11.11 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | 462 Thousand | - | - | - |
| Change in working capital | 28.3 Million | -19.91 Million | 14.26 Million | -10.27 Million | 4.3 Million |
| Other non-cash items | -1.95 Million | -1.21 Million | -1.14 Million | -1.39 Million | 379.99 Thousand |
| Investing Cash Flow | -3.89 Million | -1.11 Million | 19.79 Million | 31.85 Million | 1.92 Million |
| Investments in PPE | -8.11 Million | -435 Thousand | -3.2 Million | -638 Thousand | -283 Thousand |
| Acquisitions | - | 3.32 Million | - | - | - |
| Investment purchases | -36 Thousand | -6 Million | 8 Million | 21.5 Million | - |
| Sales/Maturities of investments | 3.56 Million | - | 17.54 Million | 8.38 Million | - |
| Other Investing Activities | 692 Thousand | 1.94 Million | -2.54 Million | 351 Thousand | 2.21 Million |
| Financing Cash Flow | -3.25 Million | 20.57 Million | -5.49 Million | -5.56 Million | -8.13 Million |
| Debt repayment | -3.25 Million | -3.43 Million | -5.49 Million | -5.62 Million | -5.36 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -2.76 Million |
| Common Stock Issuance | - | 3 Million | - | - | - |
| Other Financing Activities | -3.25 Million | 21 Million | - | 60 Thousand | -2.76 Million |
| Accounts receivables | 10.24 Million | -9.91 Million | 2.4 Million | 798 Thousand | 4.4 Million |
| Accounts payables | 16.15 Million | - | - | - | - |
| Inventory | 2.1 Million | 4.89 Million | -10.28 Million | 323 Thousand | -1 Million |
| Other working capital | 201 Thousand | 5.96 Million | -3.15 Million | -466 Thousand | 902 Thousand |
| Cash at beginning of period | 63.75 Million | 75.95 Million | 74.58 Million | 65.47 Million | 215.92 Million |
| Cash at end of period | 68.64 Million | 63.75 Million | 75.95 Million | 74.58 Million | 200.47 Million |
| Capital Expenditure | -8.11 Million | -435 Thousand | -3.2 Million | -638 Thousand | -283 Thousand |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 4.88 Million | -12.19 Million | 1.36 Million | 9.1 Million | -15.44 Million |
| Free Cash Flow | 3.92 Million | -32.08 Million | -16.13 Million | -17.81 Million | -9.52 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -4.89 Million | -4.89 Million | -8.32 Million | -21.81 Million | -8.32 Million | -2.58 Million |
| Depreciation & Amortization | 1.7 Million | 1.7 Million | 1.51 Million | 5.54 Million | 1.51 Million | 1.24 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 2.5 Million | 2.5 Million | 3.85 Million | 28.3 Million | 3.85 Million | 2.42 Million |
| Other non-cash items | -10.97 Million | -10.97 Million | 4.12 Million | -1.95 Million | 4.12 Million | 3.75 Million |
| Investing Cash Flow | -2.05 Million | -2.05 Million | -2.85 Million | -3.89 Million | -2.85 Million | 905 Thousand |
| Investments in PPE | -154 Thousand | -154 Thousand | -3.05 Million | -8.11 Million | -3.05 Million | -1 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -5.5 Million | - | - | -36 Thousand | - | - |
| Sales/Maturities of investments | - | - | - | 3.56 Million | - | - |
| Other Investing Activities | -1.9 Million | -1.9 Million | 202.5 Thousand | 692 Thousand | 202.5 Thousand | 1.9 Million |
| Financing Cash Flow | -994 Thousand | -994 Thousand | -815.5 Thousand | -3.25 Million | -815.5 Thousand | -812.5 Thousand |
| Debt repayment | -2000.00 | - | - | -3.25 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -994 Thousand | -994 Thousand | -815.5 Thousand | - | -815.5 Thousand | -812.5 Thousand |
| Accounts receivables | 637 Thousand | 637 Thousand | -698.5 Thousand | 10.24 Million | -698.5 Thousand | 5.82 Million |
| Accounts payables | -21.64 Million | - | - | - | - | - |
| Inventory | 2.4 Million | 2.4 Million | 812 Thousand | 2.1 Million | 812 Thousand | 239 Thousand |
| Other working capital | -534.5 Thousand | -534.5 Thousand | 3.73 Million | 201 Thousand | 3.73 Million | -3.63 Million |
| Cash at beginning of period | 75.68 Million | - | - | 63.75 Million | - | - |
| Cash at end of period | -14.7 Million | -14.7 Million | -2.49 Million | 68.64 Million | -2.49 Million | 4.93 Million |
| Capital Expenditure | -154 Thousand | -154 Thousand | -3.05 Million | -8.11 Million | -3.05 Million | -1 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -90.38 Million | -14.7 Million | -2.49 Million | 4.88 Million | -2.49 Million | 4.93 Million |
| Free Cash Flow | -11.81 Million | -11.81 Million | -1.87 Million | 3.92 Million | -1.87 Million | 3.83 Million |
UJJIVANSFB
BMGB4
UPMMY
3434
0720
THMO